IVIVA Medical, a pioneering biotech startup led by Harvard University Professor and Thoracic Surgeon Harald Ott, has won a Phase 2 KidneyX Prize. The Kidney Innovation Accelerator awarded the prize, a collaborative initiative between the American Society of Nephrology (ASN) and the U.S. Department of Health and Human Services (HHS).
Thanks to its groundbreaking work in developing a fully implantable bioartificial kidney made with proprietary 3D printing technology, IVIVA Medical will receive $1 million to continue its research and development of cell-based living therapeutics that replace the kidney’s most crucial functions.
IVIVA Medical has made a monumental stride in the field of organ replacement with its development of human-scale solute-exchange grafts. By using cutting-edge 3D printing technology, IVIVA creates finely separated hollow vascular networks. These networks are then methodically layered to construct a matrix that matches the scale of human organs. According to the company, this intricately designed matrix is populated with diverse types of cells, which then develop into functional tissue. The end product is a sophisticated, human-scale solute-exchange graft that can effectively replicate organ function, paving the way for significant advancements in organ therapeutics.
Often called “silent killers,” kidney diseases are a growing global health issue often linked to underlying conditions like diabetes, hypertension, and obesity. In the U.S., the high cost of treatment, over $100 billion annually, is attributed to expensive procedures like dialysis and kidney transplantation. Medicare spent roughly $81 billion on people with chronic kidney disease (CKD) and an additional $36 billion on end-stage renal disease treatment in 2018 alone.
More importantly, the long wait for a kidney transplant—over 100,000 people are on the U.S. transplant list, but only about 20,000 transplants are performed each year—underscores the urgent need for innovations like IVIVA Medical’s bioartificial kidney. Patients typically spend an average of five years or more on transplant waitlists, with many tragically dying before receiving surgery. Instead, IVIVA Medical aims to revolutionize this scenario by developing fully implantable bioartificial organs, providing a potential cure and a chance at a normal life for patients with organ dysfunction.
“Patients with renal failure experience not only the impact of their disease but also the inevitable side effects of existing treatments because transplant organs are only available for a few lucky recipients,” remarked IVIVA Medical Founder and CEO Harald Ott. “We’re working to transform organ replacement. Because we build these implants from patient-derived cells, there will be no need for long-term immunosuppression, no risk for rejection, and no donor organ shortage.”
As a renowned thoracic surgeon at Massachusetts General Hospital and an Associate Professor in Surgery at Harvard Medical School, Ott has a unique perspective and profound interest in regenerative medicine and stem cell therapy. Having founded IVIVA eight years ago, Ott is dedicated to finding a solution for end-stage renal disease.
Creating a fully functional bioartificial kidney has been challenging due to the organ’s complexity, which is composed of numerous cell types and responsible for multiple vital functions. However, the KidneyX prize provides IVIVA the resources to advance its technology as the company continues its quest to solve the organ transplant shortage.
“Kidney diseases are common, serious, and deadly. People with kidney diseases have demanded innovative treatment technologies and management strategies to replace dialysis,” commented John R. Sedor, a nephrologist with the Cleveland Clinic and KidneyX Steering Committee Chair. “The Artificial Kidney Prize Phase 2 winners highlight paradigm-shifting solutions in xenotranplantation and regenerative medicine that are being developed to reduce the burdens of kidney disease.”
Echoing these sentiments, U.S. Assistant Secretary for Health Rachel L. Levine added, “HHS is excited and remains committed to the partnership and to advancing kidney care. With the close of the Artificial Kidney Prize Phase 2, I couldn’t be more thrilled to congratulate the winners of the competition. This prize competition leads us to the next steps for advancements and solutions in artificial kidney developments.”
Phase 2 KidneyX Prize serves as a platform to expedite progress within the regenerative medicine, cellular engineering, tissue engineering, systems biology, and synthetic biology communities, targeting advanced research and development stages for an artificial kidney. This phase, spotlighting projects beyond initial proof-of-concept and heading towards larger studies or commercialization, provides a $1 million catalyst for winners like IVIVA Medical. The startup’s victory not only propels innovative work but also represents a beacon of hope for millions worldwide afflicted with kidney diseases, signaling a potential paradigm shift in renal failure treatment.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Ready for 2024: Additive Manufacturing Strategies Gears up to Revolutionize 3D Printing Industry Again
Additive Manufacturing Strategies (AMS) has set the stage for another groundbreaking conference, slated for February 6-8, 2024. After a banner year that surpassed all expectations, the seventh installment is poised...
Printing Money Episode 9: Cubicure, Sigma Additive, Bridge Rounds, Seed Rounds, and Yes…. More on the Stratasys Mergerocalypse
Episode 9 of Printing Money starts with some positive industry news as Alex and Danny discuss Vienna-based Cubicure being acquired by orthodontic company Align Technology. However it’s swings and roundabouts...
3D Printing Webinar and Event Roundup: September 17, 2023
It’s another busy week filled with 3D printing webinars and events! Topics include photopolymers and industrial automation, aerospace and 3D scanning, DIGITAL FOAM and composite 3D printers, biomaterial bioinks, and...
3D Printing News Briefs, September 16, 2023: Certification, Fuel Cells, Microalgae Ink, & More
In today’s 3D Printing News Briefs, we’re kicking things off with business, as former Waymo legal executive David Tressler joins 6K as its Chief Legal Officer. Moving on, MakerVerse received...
Upload your 3D Models and get them printed quickly and efficiently.